[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:mrc1-wt-allele":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","MRC1 wt Allele",22,[8,16,23,30,36,42,48,55,61,67,73,79,85,91,97,103,109,115,121,127,133,140],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07403721","AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H\u002FdMMR Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:18:17.950264Z","2026-05-05T02:43:26.954091Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04165772","Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors",[20],"Phase 2","2026-08-26T02:19:11.399072Z","2026-07-05T05:32:16.775552Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT05784688","Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors",[27],"Phase 1\u002FPhase 2","2026-08-26T02:18:40.612983Z","2026-05-05T02:43:29.298307Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06974110","Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:28.849469Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07094204","A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",[12],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.482220Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07213609","A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",[27],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.666743Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT06824363","ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w\u002FARID1a Mu",[52],"Early Phase 1","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:26.849550Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06562192","Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",[12],"2026-08-26T02:19:03.581490Z","2026-07-30T01:46:14.467786Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05684965","XTX301 in Patients With Advanced Solid Tumors",[27],"2026-08-26T02:17:30.961790Z","2026-07-05T05:32:16.814936Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[27],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06796907","A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors",[27],"2026-08-26T02:15:21.365312Z","2026-05-29T15:36:40.171786Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[12],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.735881Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT05592626","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",[27],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:29.329011Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05669430","A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",[27],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.900585Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07262619","EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors",[27],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.515153Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT04787042","Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",[27],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:27.747454Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06362369","A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",[27],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:27.135162Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT05086692","A Beta-only IL-2 ImmunoTherapY Study",[27],"2026-08-26T02:18:31.164304Z","2026-05-05T02:35:31.708594Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT04198766","Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",[27],"2026-08-26T02:19:08.084946Z","2026-07-30T01:46:14.442744Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06349642","Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform",[],"2026-08-26T02:17:03.534765Z","2026-05-13T02:55:06.483978Z",{"nct_id":134,"title":135,"phases":136,"status":137,"updated_at":138,"content_modified":139},"NCT05787587","A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:00:20.303350Z","2026-05-05T02:43:27.758641Z",{"nct_id":141,"title":142,"phases":143,"status":137,"updated_at":144,"content_modified":145},"NCT03935893","Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers",[20],"2026-08-03T03:19:35.241322Z","2026-05-05T02:43:26.987294Z"]